MedTrace Logo

A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I

NCT04461886 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-05-24

No results posted yet for this study

Summary

The purpose of this tria is to evaluate the safety and efficacy of long-term treatment with NPC-12G gel to patients with neurofibromatosis type I.

Conditions

  • Neurofibromatosis

Interventions

DRUG

NPC-12G gel

NPC-12G gel is containing 0.2% Sirolimus

Sponsors & Collaborators

  • Nobelpharma

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-08
Primary Completion
2021-12-07
Completion
2021-12-07

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04461886 on ClinicalTrials.gov